BACKGROUND Bone marrow transplantation(BMT)is a breakthrough procedure for patients with hematological and oncological conditions,particularly when all other treat-ments fail.Its indications vary between patients and ...BACKGROUND Bone marrow transplantation(BMT)is a breakthrough procedure for patients with hematological and oncological conditions,particularly when all other treat-ments fail.Its indications vary between patients and settings,and its outcomes depend on the donor type,transplantation facility,and center expertise.In coun-tries where transplantation facilities are lacking,sending patients abroad for transplantation might be a safe and effective alternative to leaving the patient to face eventual disease morbidity or even mortality if the procedure is not per-formed locally.However,studies evaluating BMT abroad are scarce.AIM To assess the clinical characteristics of patients who underwent BMT overseas and analyze the factors affecting their survival outcomes.METHODS We conducted a retrospective cohort study of all Bahraini pediatric patients who underwent BMT between 2013 and 2024.Medical records from Salmaniya Medical Complex and Overseas Treatment Office were reviewed.Patient demographics,RESULTS Of the 75 listed patients,62(82.7%)underwent BMT and were included,10(13.3%)did not,and 3(4.0%)were awaiting transplantation.Most patients were male(n=33,53.2%).The mean age at transplantation was 7.8±4.9 years.The main indication for treatment was acute myeloid leukemia(AML)(n=15,36.6%).Six patients(9.7%)required re-transplantation.Of the 68 transplants,60(88.2%)involved conditioning,mostly a combination of fludarabine and total body irradiation(n=7,11.7%).Most patients underwent allogeneic transplantation(n=48,77.4%),primarily from related donors(n=47/48,97.9%).The most common complication was infection(n=51,79.7%).Follow-up averaged 3.3±2.5 years.The overall survival rate was 77.4%.Survival odds were better for non-AML patients and Middle Eastern centers(P=0.015 and P=0.032,respectively).CONCLUSION Bahraini males with AML primarily underwent allogeneic BMT.Non-AML patients and those transplanted in the Middle East had better survival rates,despite high complication rates.展开更多
文摘BACKGROUND Bone marrow transplantation(BMT)is a breakthrough procedure for patients with hematological and oncological conditions,particularly when all other treat-ments fail.Its indications vary between patients and settings,and its outcomes depend on the donor type,transplantation facility,and center expertise.In coun-tries where transplantation facilities are lacking,sending patients abroad for transplantation might be a safe and effective alternative to leaving the patient to face eventual disease morbidity or even mortality if the procedure is not per-formed locally.However,studies evaluating BMT abroad are scarce.AIM To assess the clinical characteristics of patients who underwent BMT overseas and analyze the factors affecting their survival outcomes.METHODS We conducted a retrospective cohort study of all Bahraini pediatric patients who underwent BMT between 2013 and 2024.Medical records from Salmaniya Medical Complex and Overseas Treatment Office were reviewed.Patient demographics,RESULTS Of the 75 listed patients,62(82.7%)underwent BMT and were included,10(13.3%)did not,and 3(4.0%)were awaiting transplantation.Most patients were male(n=33,53.2%).The mean age at transplantation was 7.8±4.9 years.The main indication for treatment was acute myeloid leukemia(AML)(n=15,36.6%).Six patients(9.7%)required re-transplantation.Of the 68 transplants,60(88.2%)involved conditioning,mostly a combination of fludarabine and total body irradiation(n=7,11.7%).Most patients underwent allogeneic transplantation(n=48,77.4%),primarily from related donors(n=47/48,97.9%).The most common complication was infection(n=51,79.7%).Follow-up averaged 3.3±2.5 years.The overall survival rate was 77.4%.Survival odds were better for non-AML patients and Middle Eastern centers(P=0.015 and P=0.032,respectively).CONCLUSION Bahraini males with AML primarily underwent allogeneic BMT.Non-AML patients and those transplanted in the Middle East had better survival rates,despite high complication rates.
